huCD7/huCD19 Mouse

CD7 is mainly expressed in T cells and natural killer (NK) cells. It is expressed throughout thymocyte development from early stages to mature T cells, and also in some hematopoietic progenitor cells, but its expression level is low in most normal non-T-cell and non-NK-cell tissues. Abnormal expression or signaling dysregulation of CD7 is closely associated with various diseases. As an important target for immunotherapy, CD7 has become a key molecule for targeting T-cell malignancies due to its high expression in T-cell acute lymphoblastic leukemia (T-ALL), T-cell lymphoma, and other T-cell malignant tumors ^[1]. The CD19 gene encodes a member of the immunoglobulin gene superfamily. As a key co-receptor in the B-cell receptor (BCR) signaling pathway, it is essential for B-cell development, activation, and differentiation. CD19 is a pan-B-cell marker, expressed only in the B-cell lineage, and is stably expressed throughout B-cell development (from pre-B cells to mature B cells and memory B cells). CD19 is a positive regulatory factor for BCR signal transduction. This protein forms a B-cell-specific signaling complex with CD21 (complement receptor 2), CD81 (tetraspanin), and CD225 (Leu13), which lowers the threshold for antigen-induced B-cell activation ^[2]. Dysregulation of CD19 is closely related to autoimmune diseases such as systemic lupus erythematosus (SLE) and B-cell malignancies including acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma. Mutations in this gene are associated with common variable immunodeficiency 3 (CVID3), manifesting as impaired B-cell differentiation and hypogammaglobulinemia. Due to its B-cell-specific expression, CD19 has become an important target for immunotherapy. For example, anti-CD19 CAR-T cell therapy (e.g., tisagenlecleucel) has shown significant efficacy in refractory or relapsed acute lymphoblastic leukemia ^[3]. Recent studies have also explored bispecific antibodies targeting CD19 (e.g., blinatumomab) to enhance the clearance of tumor cells ^[4].

The huCD7/huCD19 mouse is a dual-gene humanized model obtained by crossing the huCD7 mouse (Catalog No.: C002067) with the huCD19 mouse (Catalog No.: C001731). This model can be used for studying the immune mechanisms of CD7/CD19-related malignancies, as well as for screening, efficacy evaluation, and safety assessment of drugs targeting CD7/CD19.